Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors
Authors' conclusion
Untreated aGHD potentially contributes to multidimensional adverse outcomes, and GHT may provide health benefits among survivors, though socioeconomic disadvantage may limit their access to GHT.
Study context
- Population
- 5-year survivors of childhood cancer aged 18 years and older
- Participants
- 3,902 survivors
- Exposure
- Low IGF-1 vs normal IGF-1; Growth hormone therapy (GHT) use by socioeconomic factors
- Outcome
- Adverse outcomes, low vs normal IGF-1
Methodological detailsmultivariable logistic regression adjusting for potential confounders
- Multivariable logistic regression adjusting for potential confounders
Main finding
As reported in the abstract
Low IGF1 vs Normal IGF1Odds ratio (95% CI)
Verbal reasoning impairment
2.79(1.95–3.98)
Diminished HRQoL: physical functioning
1.97(1.35–2.86)
Abnormal glucose metabolism
1.82(1.21–2.71)
Abnormal fat percentage
3.16(1.98–5.26)
Observational data: associations, not effects.
Further findings
GHT use among survivors with severe adult growth hormone deficiency (aGHD) (n=354)
- On GHT
- 9.0%
- OR of GHT use, annual household income <$40 000 vs ≥$80 000
- 0.27 (95% CI, 0.08-0.84)
- Socioeconomic disadvantages independently associated with less GHT use
Original publication
Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors. J Clin Endocrinol Metab. Published 8 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →